No Data
No Data
Institutional Owners May Take Dramatic Actions as Zai Lab Limited's (NASDAQ:ZLAB) Recent 4.4% Drop Adds to One-year Losses
Key Insights Institutions' substantial holdings in Zai Lab implies that they have significant influence over the company's share price 51% of the business is held by the top 9 shareholders Ownersh
Asian Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading, End Week Lower
Asian equities traded in the US as American depositary receipts were trending higher Friday morning, rising 1.01% to 1,951.87 on the S&P Asia 50 ADR Index. Despite the gain, the index is set to close
Zai Lab Doses First Subject in Phase II Plaque Psoriasis Treatment Trial
Zai Lab Initiates Global Phase 2 Clinical Trial Evaluating ZL-1102 As a Topical Treatment for Chronic Plaque Psoriasis
This is the first compound in Zai's portfolio of internally developed drugs to advance into Phase 2, demonstrating Zai's global capabilities Based on a proof-of-concept study, ZL-1102 is the first topical biologic to
Zai Lab, Innoviva Subsidiary Receive China Approval for Hospital Infection Treatment
Zai Lab (ZLAB) and Innoviva's (INVA) Specialty Therapeutics subsidiary said Monday China's National Medical Products Administration has approved Zai's new drug application for Xacduro, the two firms'
Zai Lab, Innoviva: China Oks XACDURO For Hospital-Acquired, Ventilator-Associated Pneumonia In 18+
No Data